Privacy Policy This website gathers information about visits to the pages on our servers. We maintain statistics that show the total number of visitors to our web sites, requests we receive for pages on our web sites and what domains or Internet service providers those requests come from. We use this information internally to improve our services and for protection of our intellectual property. Although this information may be provided to others, it does not contain personal information about individual web site users such as social security numbers or other personal identifiers. How Can We Help You? Get in touch with us or explore our offerings. "Establishing a relationship with Healix has allowed us to provide our patients with outstanding care while being able to control the clinical situation and achieve the best possible outcomes." Andrew Krinsky, MD Infectious Diseases Associates, Sarasota, Florida Contact usPrivacy PolicyTerms and conditionsADP employee loginClient loginPaycom Employee Login web design © Healix Infusion Therapy

Immunoglobulin National Society (IgNS) National Conference October 21, 2021 Healix is proud to participate with our clients in the Immunoglobulin National Society (IgNS) 10th National Conference, presenting our collaborative clinical research. Speak with presenting author Lucinda J. Van Anglen, B.S., Pharm.D., during the IgNS Poster Session on Friday, October 22, from 5:30 to 7:00 PM for a live discussion at this year’s conference. (Poster #21) Real-World Evaluation of Immune Globulin Subcutaneous 16.5% in the Treatment of Primary Immunodeficiency: One-Year Outcomes Lucinda J. Van Anglen, PharmD1; Jeffrey W. Langford, MD, AE-C2; Richard F. Herrscher, MD, FACAAI3; Samantha A. Mehta, PharmD1 1Healix Infusion Therapy, LLC, Sugar Land, TX; 2Langford Allergy, LLC, Macon, GA; 3AIR Care, Dallas, TX Immunoglobulin National Society (IgNS), 10th National Conference is live in-person and virtual, October 21-24, 2022, at the Red Rock Casino Resort & Spa, Las Vegas, Nevada. To learn more about our outcomes research and how Healix can help you establish an office infusion center or outsource the management of an existing operation contact us contact us today! View All Previous Next Phase II And Phase III Studies Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease. For information on partnering with Healix on a study, please contact us. Contact usPrivacy PolicyTerms and conditionsADP employee loginClient loginPaycom Employee Login web design © Healix Infusion Therapy